Real-world use of ticagrelor and prasugrel in patients with NSTEMI undergoing percutaneous coronary intervention

    loading  Checking for direct PDF access through Ovid


Dual antiplatelet therapy is mandatory for all the patients with acute coronary syndrome, who underwent percutaneous coronary intervention (PCI).1 Prasugrel and ticagrelor, new inhibitors of the platelet adenosine diphosphate receptor P2Y12, should be preferred to clopidogrel.2,3 The next study sought to describe the safety and efficacy profile of both prasugrel and ticagrelor in patients with Non-ST-segment elevation myocardial infarction (NSTEMI), who were admitted to coronary ICU and underwent primary PCI.

Related Topics

    loading  Loading Related Articles